HomeAbout UsContact Us1-800-688-2421
Medical Device Daily
Advanced Search

User ID

Password

Forgot password

Remember my login



New User ?

Products & Services
Medical Device Daily
Biomedical Business & Technology
Cardiovascular Devices & Drugs
Diagnostics & Imaging Week
Medtech Resources
Biotechnology and Medical Device VC Directory 2009
Nanotechnology Report 2009
Arthritis Report 2009
MDD Perspectives
Audio Conferences
BioWorld Today
Biotech Resources
Market Insight
Clinical Trials
PMA and 501(k) Approvals
Today's Issue of Medical Device Daily

Thursday, July 2, 2009

Today's Headlines

Financings roundup: SBi raises $108M 'D' round; Lumenis gets $15 million

At a time when medical device companies are struggling to keep afloat it is refreshing to see there are still some companies out there that have managed to bring in some significant cash. (Medical Device Daily)

The BB&T interview: Hans Hofstraat, Vice president, Philips Research

While competitors rapidly buy their way into the breaking new field of molecular medicine, Philips Healthcare is pursing what might be called a green-field approach to the market, seeking to build new technologies from the ground up and to discover novel biomarkers from scratch. While it seems to be a strategy in keeping with the company's slogan of 'Sense and Simplicity,' Philips could instead be seen as taking a cautious approach to what is a promising but unproven opportunity. (Biomedical Business & Technology)

There's no Expiration on this Knowledge, but the Education Opportunity will Expire July 31!

Catch up on what you've missed for 40% off! This is your opportunity to get in the know and listen to noted speakers in the industry discuss current topics affecting your business today. BioWorld Today and Medical Device Daily offers this special rate through July 31, 2009. Click here and order now!

Exosome, DxS collaborating on blood-based cancer tests

The days of cutting out cancerous tissue to examine under a microscope for a firm diagnosis may be numbered. By next year, Exosome Diagnostics (New York) expects to have blood-based cancer diagnostics on the market. (Diagnostics & Imaging Week)


Is the FDA asking too much of your 510(k)? — On May 12, the FDA announced they would be "re-examining" Menaflex, a device cleared for marketing via 510(k). Will more devices follow? In this 90-minute audio conference scheduled for July 8th, device submissions expert Mark DuVal will discuss what FDA is asking for in 510(k) submissions, and how you can effectively respond to FDA's ever increasing demands for more medical and scientific information. Click here for more details.

MDD Home   |   About MDD   |   Contact Us
Copyright Notices   |   Terms of Use   |   Privacy Statement